Newsroom Archives - Page 3 of 23 - Spectral Medical Inc

Spectral Medical Receives US$3 Million From Vantive

TORONTO, Canada – August 25, 2025 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that it has received the US$3 million Tranche B...

Spectral Medical and Vantive Announce Topline Results from Spectral’s TIGRIS Trial Evaluating PMX Hemoadsorption Therapy for Endotoxic Septic Shock

Results exceed prespecified primary endpoint of 95% posterior probability of benefit for PMX on 28-day mortality. Pooled absolute risk reduction of 8.3%; Relative risk reduction of 18% Key secondary endpoint: 90-day Mortality 17.4% lower with PMX and >99%...

Spectral Medical Announces Second Quarter and Provides Corporate Update

Topline Tigris results expected to be released around mid-August 2025. TORONTO, Canada – August 8, 2025 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock,...

Spectral Medical Inc. Announces Filing of Base Shelf Prospectus

TORONTO, Canada – July 4, 2025 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that it has filed a preliminary short form base shelf...

Spectral Medical Inc. Announces Results of Annual Meeting of Shareholders

TORONTO, Canada – June 6, 2025 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the results of its Annual Meeting of shareholders (the...

Spectral Medical to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

TORONTO, Canada – May 16, 2025 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that management will participate in a fireside chat at...

« Older Entries

Next Entries »

EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.